Allergan Freedom From Expression Suit Challenges REMS, Off-Label Powers
Executive Summary
Allergan's suit against FDA seeking a court ruling that it can provide physicians with information on unapproved uses of Botox is another milestone in the debate over off-label promotion, but it also may be the first legal indication of the power of Risk Evaluation and Mitigation Strategies to impact sales